CAR T-cell therapy for immune-mediated necrotizing myopathy
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This trial tests a new treatment called Eque-cel, which uses your own immune cells to target and destroy the cells causing muscle damage. It is for people with a specific type of inflammatory muscle disease that has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with immune-mediated necrotizing myopathy (IMNM).
- Your blood tests show a positive anti-SRP or anti-HMGCR antibody.
- You have tried standard treatments but your disease is still active or has come back.
- You agree to use effective birth control during the study and for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of cancer treatment called CAR-T cell therapy for people with multiple myeloma that has relapsed (come back) or is refractory (did not respond to treatment). The treatment uses your own immune cells to attack the cancer. This study is real-world, meaning it happens in everyday clinical practice, not in a strict research setting.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This trial tests a new treatment called RD06-04, which uses your own immune cells modified to target a protein on faulty immune cells. It aims to reduce the autoimmune attack in two rare conditions and may help people who have not found relief from other treatments.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new Refractory Immune-mediated Necrotizing Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.